Roy M. Bremnes

17.2k total citations · 2 hit papers
229 papers, 13.0k citations indexed

About

Roy M. Bremnes is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Roy M. Bremnes has authored 229 papers receiving a total of 13.0k indexed citations (citations by other indexed papers that have themselves been cited), including 110 papers in Oncology, 79 papers in Pulmonary and Respiratory Medicine and 71 papers in Molecular Biology. Recurrent topics in Roy M. Bremnes's work include Lung Cancer Treatments and Mutations (45 papers), Testicular diseases and treatments (34 papers) and Lung Cancer Research Studies (32 papers). Roy M. Bremnes is often cited by papers focused on Lung Cancer Treatments and Mutations (45 papers), Testicular diseases and treatments (34 papers) and Lung Cancer Research Studies (32 papers). Roy M. Bremnes collaborates with scholars based in Norway, Spain and United States. Roy M. Bremnes's co-authors include Tom Dønnem, Lill‐Tove Busund, Samer Al‐Saad, Sigve Andersen, Khalid Al‐Shibli, Rafael Sirera, Carlos Camps, Wilbur A. Franklin, Olbjørn Klepp and Robert Veve and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and PLoS ONE.

In The Last Decade

Roy M. Bremnes

227 papers receiving 12.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Epidermal Growth Factor Receptor in Non–Small-Cell Lung Carcinomas: Correlation Between Gene Copy Number and Protein Expression and Impact on Prognosis

2003 1.2k citations Roy M. Bremnes et al. Journal of Clinical Oncology profile →
The Role of Tumor Stroma in Cancer Progression and Prognosis: Emphasis on Carcinoma-Associated Fibroblasts and Non-small Cell Lung Cancer

2010 525 citations Roy M. Bremnes, Tom Dønnem et al. Journal of Thoracic Oncology profile →

Peers

Countries citing papers authored by Roy M. Bremnes

Since Specialization

Citations

This map shows the geographic impact of Roy M. Bremnes's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Roy M. Bremnes with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Roy M. Bremnes more than expected).

Fields of papers citing papers by Roy M. Bremnes

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Roy M. Bremnes. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Roy M. Bremnes. The network helps show where Roy M. Bremnes may publish in the future.

Co-authorship network of co-authors of Roy M. Bremnes

This figure shows the co-authorship network connecting the top 25 collaborators of Roy M. Bremnes. A scholar is included among the top collaborators of Roy M. Bremnes based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Roy M. Bremnes. Roy M. Bremnes is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Low Expression of miR-424-3p is Highly Correlated with Clinical Failure in Prostate Cancer 2019 ·Scientific Reports ·Elin Richardsen, Sigve Andersen, Samer Al‐Saad, Mehrdad Rakaee, Yngve Nordby, Mona Irene Pedersen, Nora Ness, (unknown), Ambrogio Fassina, Kristin Austlid Taskén, Ian G. Mills, Tom Dønnem, Roy M. Bremnes, L. T. Busund	28
2	Expression of phosphatase of regenerating liver (PRL)-3, is independently associated with biochemical failure, clinical failure and death in prostate cancer 2017 ·PLoS ONE ·Sigve Andersen, Elin Richardsen, Mehrdad Rakaee, Helena Bertilsson, Roy M. Bremnes, Magne Børset, Lill‐Tove Busund, Tobias S. Slørdahl	2
3	Assessing PDL-1 and PD-1 in Non–Small Cell Lung Cancer: A Novel Immunoscore Approach 2016 ·Clinical Lung Cancer ·Erna‐Elise Paulsen, Thomas K. Kilvær, Mehrdad Rakaee, Samer Al‐Saad, Sigurd M. Hald, Sigve Andersen, Elin Richardsen, Nora Ness, Lill‐Tove Busund, Roy M. Bremnes, Tom Dønnem	72
4	Estrogen receptors α and β and aromatase as independent predictors for prostate cancer outcome 2016 ·Scientific Reports ·(unknown), (unknown), Sigve Andersen, Nora Ness, Yngve Nordby, Samer Al‐Saad, Silje Fismen, Tom Dønnem, Mehrdad Rakaee, Lill‐Tove Busund, Roy M. Bremnes, Elin Richardsen	32
5	Skeletal muscle radiodensity is prognostic for survival in patients with advanced non-small cell lung cancer 2016 ·Clinical Nutrition ·(unknown), Bjørn Henning Grønberg, Tore Wentzel‐Larsen, Vickie E. Baracos, Marianne Jensen Hjermstad, Nina Aass, Roy M. Bremnes, Øystein Fløtten, Asta Bye, Marit Slaaen	112
6	Stromal CD8+ T-cell Density—A Promising Supplement to TNM Staging in Non–Small Cell Lung Cancer 2015 ·Clinical Cancer Research ·Tom Dønnem, Sigurd M. Hald, Erna‐Elise Paulsen, Elin Richardsen, Samer Al‐Saad, Thomas K. Kilvær, Odd Terje Brustugun, Åslaug Helland, Marius Lund‐Iversen, Mette Poehl, Karen Ege Olsen, Henrik J. Ditzel, Olfred Hansen, Khalid Al‐Shibli, Yury Kiselev, Torkjel M. Sandanger, Sigve Andersen, Francesco Pezzella, Roy M. Bremnes, Lill‐Tove Busund	252
7	How Do Elderly Poor Prognosis Patients Tolerate Palliative Concurrent Chemoradiotherapy for Locally Advanced Non–Small-Cell Lung Cancer Stage III? A Subset Analysis From a Clinical Phase III Trial 2014 ·Clinical Lung Cancer ·(unknown), Roy M. Bremnes, Stein Sundstrøm, (unknown), Ulf Aasebø	14
8	Monocarboxylate Transporters 1–4 in NSCLC: MCT1 Is an Independent Prognostic Marker for Survival 2014 ·PLoS ONE ·(unknown), Sigve Andersen, Samer Al‐Saad, Yury Kiselev, Tom Dønnem, Helge Stenvold, Ingvild Pettersen, Khalid Al‐Shibli, Elin Richardsen, Lill‐Tove Busund, Roy M. Bremnes	63
9	A population-based study of the pattern of terminal care and hospital death in patients with non-small cell lung cancer. 2012 ·PubMed ·Carsten Nieder, Terje Tollåli, Jan Norum, Adam Pawinski, Roy M. Bremnes	13
10	MicroRNA Signatures in Tumor Tissue Related to Angiogenesis in Non-Small Cell Lung Cancer 2012 ·PLoS ONE ·Tom Dønnem, Christopher G. Fenton, (unknown), Thomas Berg, (unknown), Sigve Andersen, Helge Stenvold, Khalid Al‐Shibli, Samer Al‐Saad, Roy M. Bremnes, Lill‐Tove Busund	91
11	Management of Seminomatous Testicular Cancer: A Binational Prospective Population-Based Study From the Swedish Norwegian Testicular Cancer Study Group 2011 ·Journal of Clinical Oncology ·Torgrim Tandstad, Rune Smaaland, Arne Solberg, Roy M. Bremnes, Carl W. Langberg, Anna Laurell, Ulrika Stierner, Olof Ståhl, Eva Cavallin‐Ståhl, Olbjørn Klepp, Olav Dahl, Gabriella Cohn‐Cedermark	141
12	Correlation and coexpression of HIFs and NOTCH markers in NSCLC. 2011 ·PubMed ·Sigve Andersen, Tom Dønnem, Samer Al‐Saad, Khalid Al‐Shibli, Helge Stenvold, Lill‐Tove Busund, Roy M. Bremnes	14
13	Prognostic Impact of Angiogenic Markers in Non–Small-Cell Lung Cancer is Related to Tumor Size 2011 ·Clinical Lung Cancer ·Tom Dønnem, Sigve Andersen, Samer Al‐Saad, Khalid Al‐Shibli, Lill‐Tove Busund, Roy M. Bremnes	20
14	Long-term follow-up after risk-adapted treatment in clinical stage 1 (CS1) nonseminomatous germ-cell testicular cancer (NSGCT) implementing adjuvant CVB chemotherapy. A SWENOTECA study 2010 ·Annals of Oncology ·Torgrim Tandstad, Gabriella Cohn‐Cedermark, O. Dahl, Ulrika Stierner, Eva Cavallin‐Ståhl, Roy M. Bremnes, Olbjørn Klepp	34
15	Chemotherapy and quality of life in NSCLC PS 2 patients 2009 ·Acta Oncologica ·(unknown), (unknown), Stein Sundstrøm, Ulf Aasebø, Christian von Plessen, Roy M. Bremnes, (unknown)	11
16	Prognostic Scores in Patients with Brain Metastases from Non-small Cell Lung Cancer 2009 ·Journal of Thoracic Oncology ·Carsten Nieder, Roy M. Bremnes, Nicolaus Andratschke	31
17	Prognostic Impact of Platelet-Derived Growth Factors in Non-small Cell Lung Cancer Tumor and Stromal Cells 2008 ·Journal of Thoracic Oncology ·Tom Dønnem, Samer Al‐Saad, Khalid Al‐Shibli, Sigve Andersen, Lill‐Tove Busund, Roy M. Bremnes	96
18	Is the Sexual Function Compromised in Long-Term Testicular Cancer Survivors? 2007 ·European Urology ·Alv A. Dahl, Roy M. Bremnes, Olav Dahl, Olbjørn Klepp, Erik Wist, Sophie D. Fosså	88
19	Experience with and attitudes to chemotherapy among newly employed nurses in oncological and surgical departments 1999 ·Supportive Care in Cancer ·Roy M. Bremnes	2
20	Dose-dependent pharmacokinetics of methotrexate and 7-hydroxymethotrexate in the rat in vivo. 1989 ·PubMed ·Roy M. Bremnes, (unknown), E. Wist, Jarle Aarbakke	38

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact